Investigational drug · Phase 2
AZD3470
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "AZD3470"
First trial start
2024
Jan 18, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD3470", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lymphoma
- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma
- Peripheral T-cell Lymphoma (PTCL)
- PTCL-NOS
- ALCL
- AITL
- Advanced Solid Tumors That Are MTAP Deficient
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Oncology · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD3470" as an intervention, largest first.
AstraZenecaAstraZeneca (AZN)
NCT06130553 · 334 participants (planned) · Start Jan 18, 2024 · Primary completion Dec 4, 2028
Drug: AZD3470; Datopotamab deruxtecan · For: Advanced Solid Tumors That Are MTAP Deficient
Sites: San Francisco, California; West Hollywood, California; New Haven, Connecticut · 21 sites in all
- AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06137144 · 161 participants (planned) · Start Jan 23, 2024 · Primary completion May 3, 2029
Drug: AZD3470; Pembrolizumab · For: Lymphoma; Non-Hodgkin Lymphoma; Hodgkin Lymphoma and 4 more
Sites: Duarte, California; Miami, Florida; Atlanta, Georgia · 38 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Quantitative Global Proteomics of Formalin-Fixed Paraffin-Embedded Tumors Identifies Dimethylated G3BP1 at Arginine 460 as a Robust Pharmacodynamic Biomarker of Methylthioadenosine Phosphorylase-Selective Protein Arginine Methyltransferase 5 Inhibition.
Tu A, Wiseman EJ, Sweet SM, et al. · J Proteome Res 2026
- Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical Evaluation.
Smith JM, Barlaam B, Beattie D, et al. · J Med Chem 2026
Also in development for Lymphoma
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- OSE2101Phase 32 trials
OSE Immunotherapeutics · Patients With Non-Small Cell Lung Cancer, Solid Advanced Tumor, Lymphoma
- GecacitinibPhase 24 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Lymphoma, Non-small Cell Lung Cancer, Advanced Solid Tumor
- COH04S1GEO-CM04S1, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1Phase 22 trials
GeoVax, Inc. · COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia
- ASTX660Phase 21 trial
Taiho Oncology, Inc. · Solid Tumors, Lymphoma
- BT02Phase 21 trial
Biotroy Therapeutics · Relapsed or Refractory Hematologic Malignancies, Leukemia, Lymphoma
- CTS3497Phase 21 trial
CytosinLab Therapeutics Co., Ltd. · Solid Tumor, Lymphoma
- EB103Phase 21 trial
Estrella Immunopharma, Inc. · B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.